Concerns about the ALIFE2 trial

Lancet. 2024 Jan 20;403(10423):246-247. doi: 10.1016/S0140-6736(23)02339-5.

Authors

Ryu Yanagisawa¹, Shin-Ichiro Fujiwara², Tomohiko Sato³

Affiliations

¹ Division of Blood Transfusion, Shinshu University Hospital, Nagano, Japan.
² Division of Cell Transplantation and Transfusion, Jichi Medical University Hospital, Tochigi, Japan.
³ Division of Transfusion Medicine and Cell Therapy, The Jikei University Hospital, Tokyo 1058471, Japan. Electronic address: tomosatou@jikei.ac.jp.

PMID: 38245242
DOI: 10.1016/S0140-6736(23)02339-5

No abstract available

Publication types

Letter